Clinical Trial Update: A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects. [Phase 2]

View source ↗

Summary

Phase 2 double-blind, randomized trial comparing Epanova to fenofibrate on liver fat in overweight individuals with NAFLD or hypertriglyceridemia; trial complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Epanova (icosapent ethyl)
• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: AstraZeneca | Conditions: Non-alcoholic Fatty Liver Disease (NAFLD, Hypertriglyceridemia | Phase 2 | Status: COMPLETED | Results posted: 2018-09-25